"Designing Growth Strategies is in our DNA"
Hyperalgesia refers to a medical condition where the individual develops an increased sensitivity to pain. Conditions and stimuli which do not normally cause hurt in individuals without the condition lead to significant pain in individuals with hyperalgesia. There are different types of hyperalgesia such as primary, secondary and opioid-induced hyperalgesia (OIH). Hyperalgesia is considered a form of neuropathic pain, where the pain results from the damage to the nervous system. A number of potential causes can lead to the development of hyperalgesia but the condition is thought to be a result of changes to nerve pathways.
Current treatment of hyperalgesia includes the use of pain medications for the treatment of neuropathic pain. Drugs like selective serotonin reuptake inhibitors (SSRI) and nonsteroidal anti-inflammatory drugs (NSAIDs) are being used for the treatment of hyperalgesia. For the individuals suffering from opioid-induced hyperalgesia (OIH), the doctor may reduce the dosage of the individual’s opioid medications. Initially, the individual suffers from heightened pain after the reduction of dosage, but the pain eventually subsides and leads the way towards better pain management.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for Hyperalgesia. For instance; ABX-1431, which is being studied by Abide Therapeutics, Inc., is currently in phase-1 clinical trials for an fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and its Neural Correlates.
To know how our report can help streamline your business, Speak to Analyst
At present, around 63% of the pipeline candidates for Hyperalgesia are in the phase-2 and phase-4 stages combined. A minority of these studies are being sponsored by the industry.
The report on ‘Hyperalgesia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Hyperalgesia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Hyperalgesia.
The report on ‘Hyperalgesia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.
Reasons to Buy this Report